Various studies have shown that the IL-6/JAK2/STAT3 pathway is upregulated in basal-like BC cells, and it has been stated by Marotta LL et al. that NBP-BSK805 and other inhibitors (Table 6) abrogates the growth of patient-derived breast tumor xenografts (Banerjee and Resat, 2016). The gene discussed is JAK2; the disease is breast cancer.